Loss of Heterozygosity Analysis Defines a Critical Region in Chromosome Ip22 Commonly Deleted in Human Malignant Mesothelioma

Wen-Ching Lee, Binaifer Balsara, Zemin Liu, Suresh C. Jhanwar, and Joseph R. Testa

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [W-C. L., B. B., Z. L. J. R. T.], and Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [S. C. J.]

Abstract
Previous cytogenetic analysis has revealed frequent deletions of chromosome Ip21-22 in human malignant mesothelioma, suggesting that the loss or inactivation of a tumor suppressor gene(s) residing at this site may contribute to the tumorigenic conversion of mesothelial cells. To more precisely define the location of the target gene, primary tumor specimens and cell lines from 50 malignant mesotheliomas were examined for loss of heterozygosity using short tandem repeat polymorphism (STRP) markers. Nineteen STRP markers established by the Cooperative Human Linkage Center were selected for the initial screening of the entire short arm of chromosome 1. Thirty-seven cases (74%) showed allelic losses at least at one locus in Ip. Thirty-six of these cases showed losses of Ip21-22, including 23 with partial deletions involving this region. To obtain a higher resolution map of this region, another 13 STRP markers from the Genethon map were used to define the shortest region of overlapping deletions to a 4-cM segment flanked by the loci D1S435 and DIS236. The chromosomal location of the critically deleted region was confirmed to be within Ip22 by karyotyping and fluorescence in situ hybridization analyses.

Introduction
Tumorigenesis is a multistep process involving a series of acquired genetic changes, including activation of proto-oncogenes and inactivation of TSGs. Some of these changes involve gross alterations of chromosomal structure visible as cytogenetic abnormalities. In fact, the association between recurrent chromosomal abnormalities and specific types of cancer has led to the discovery of genes which, when altered, contribute to the initiation or progression of human malignancy (reviewed in Ref. 1).

MM is a neoplasm of mesodermal origin with an incidence of approximately 2000 cases annually in the United States. Exposure to asbestos has been implicated as a major contributory factor in the development of this malignancy. MM is characterized by a very long latency from the time of exposure to asbestos to the onset of disease. The length of the latent period suggests that multiple genetic alterations may be required for tumorigenic conversion of a mesothelial cell. This notion is supported by previous karyotypic analyses demonstrating that most MMs have multiple numerical and structural changes (2–4). Recurrent deletions of specific chromosomal sites in MM include Ip21–22, 9p21–22, 3p21, 6q15–21, and 22q (4), suggesting that TSGs critical to mesothelial cell tumorgenesis may reside in these regions. At the molecular genetic level, we have detected high frequencies of LOH at 3p21 in MM tumor biopsies and cell lines (5) and homozygous deletions at 9p21–22 in MM cell lines (6). We further demonstrated that CDKN2/MTS1/p16, located at 9p21–22, is homozygously deleted in many MM cell lines in addition to several tumor specimens (7). Moreover, NF2, a TSG located in chromosome 22q12, has been shown to be a frequent site of mutations in primary tumors and cell lines from patients with MM (8, 9).

In this study, the high frequency of cytogenetic deletions within Ip in MM was verified at the molecular genetic level using STRP markers. We report the results of high resolution deletion mapping of Ip using 32 cell lines and 18 tumor specimens and fine map the SRO of these deletions to a region of approximately 4 cM. In addition, we confirm the location of the SRO in Ip22 by karyotypic and FISH analyses.

Materials and Methods

Specimen Collection and Nucleic Acid Extraction. Criteria for the diagnosis of MM were in accordance with established guidelines (10). All primary MM tumors were snap-frozen and stored at −70°C prior to extraction of DNA. Thirty-two cell lines were established from surgically explanted primary MMs, as described previously (4). Genomic DNAs were purified from the cell lines and tumors by standard methods (6) and from matched blood samples with the aid of a QIAamp kit (Qiagen).

PCR and LOH Studies. All primer pairs for PCR amplification of STRP markers were obtained from Research Genetics (Huntsville, AL). Each PCR was performed in a 10-µl mixture containing 30 ng of genomic DNA, 0.4 µM of each primer, 0.64 µM dATP, 4 µCi each of dCTP, dTTP and dGTP, 1 µCi of [α-35S]dATP (DuPont NEN), and 0.4 unit of Taq DNA polymerase in GeneAmp PCR buffer (Perkin-Elmer). For most of the primer pairs, the mixtures were first heated to 94°C for 4 min and then subjected to 35 PCR cycles, each consisting of 94°C for 30 s, 57°C for 30 s, and 72°C for 30 s, with a final 5-min extension at 72°C. To improve the results obtained with some primer pairs, the annealing temperature was lowered to 55°C, and the extension time was increased to 1 min. Five µl of each PCR product was separated on 6% polyacrylamide sequencing gels. Gels were dried and then exposed to Kodak X-AR5 films for visualization. To determine band intensity differences, some dried gels were also exposed to a phosphorimaging plate and quantitated by a Fuji Bio Imaging analyzer.

Fifty cases, including 18 tumor specimens and 32 cell lines, from primary MMs were included in this study. Genomic DNA from matched blood samples was used for comparison in all of the tumor cases and 19 of the cell lines. DNA isolated from tumor explants was used to determine the constitutional heterozygosity for the other 13 cell lines (5), because no matched blood samples were available in these cases. For all cell lines, LOH was assigned to an informative locus when one allele was completely lost in the cell line. For tumor tissues, LOH was assigned if the intensity of the band from one allele was greatly reduced as compared to its corresponding normal allele. However, if the tumor DNAs showed less marked differences in intensity of allelic bands, the signals were quantitated by phosphorimaging, and LOH was assigned if the allele ratio in tumor DNA differed more than 30% from the allelic ratio in normal DNA.

Cytogenetic and FISH Analyses. Cell line 28 was used for both karyotypic and FISH studies. Actively growing cells were harvested, fixed, and...
G-banded according to standard methods (4). Ethidium bromide was added 2 h before cytogenetic harvest to extend the length of chromosomes available for banding analysis (11).

Yeast strains carrying YACs 885C5, 946C5, 957D9, and 759D7 (containing Ip loci D1S488, D1S435, D1S424, and D1S236, respectively) were obtained from Research Genetics. DNA was purified from yeast strains by standard methods. Two-color FISH was performed using biotin-16-dCTP and digoxigenin-11-dUTP. Probes were labeled by random octamer priming at 37°C for 1 h and then ethanol precipitated with Cot1 DNA. Hybridization was carried out on metaphase spreads from phytohemagglutinin-stimulated normal peripheral blood lymphocytes and cells from case 28, as described previously (12). Hybridization of biotinylated probes was detected with FITC-avidin (Oncor, Gaithersburg, MD) and digoxigenin-labeled probes with anti-digoxigenin rhodamine (Boehringer Mannheim). Chromosomes were counterstained with 4',6'-diamidino-2-phenylindole. Images of 4',6'-diamidino-2-phenylindole-stained chromosomes and hybridization signals were captured separately using a cooled CCD camera (Photometrics, Tucson, AZ), pseudo-colored, and then merged using computer imaging software from Oncor.

Results

Detection of LOH in MM by STRP Analysis. To map the region of deletion in Ip, 32 cell lines and 18 tumor specimens were examined for LOH using STRP markers. Nineteen CHLC markers (13) were selected for the initial screening. Seventeen of these STRP markers, distributed along the entire short arm (Fig. 1), were used to delineate deletions in Ip, and two others, located very close to the centromere in the long arm of chromosome 1, were used to determine if deletions extended into Iq, as would be the case for whole chromosome losses and other pericentric losses. All 50 cases were informative at several of the tested loci (range, 7-16; median, 12.5). The highest frequency of deletion was at D1S1588 (20 of 26 informative cases, 77%; Fig. 1). Frequent LOH was also observed at D1S1587 (21 of 29 informative cases, 72%) and D1S551 (21 of 31 informative cases, 68%), which flank the D1S1588 locus. The marker GCT1C9 also showed a high frequency (70%) of LOH, but only 10 cases were informative with this marker.

Overall, 37 cases (74%) showed LOH at least at one locus. Thirteen of these 37 cases (8 cell lines and 5 tumors) lost alleles at loci spanning the entire short arm of chromosome 1, and the loss extended into the long arm in 10 cases (6 cell lines and 4 primary tumors). These cases could not be used to narrow down the critically deleted region since an entire Ip or a whole chromosome 1 was lost. Intersitial and/or terminal deletions were observed in the remaining 24 cases, 23 of which involved Ip21-22 (Fig. 1). By analyzing the LOH patterns of the latter cases, the SRO of deletions was determined to be located between markers D1S551 and D1S1587, consistent with the high frequency of LOH at these loci. Case 9 defined the proximal border since one allele at D1S1588 and each informative locus distal to it was lost, but heterozygosity was retained at D1S1587 and all of the Ip loci proximal to it (Figs. 1 and 2). Cases 54, 63, and 28 defined the distal boundary of the SRO. For example, case 28 showed LOH at D1S1588 but retained heterozygosity at D1S551, the next distal locus, and all informative loci distal to it (Figs. 1 and 2). Only two cases (2 and 31) retained heterozygosity at D1S1588. In case 2, D1S534 was the sole locus that showed allelic loss. However, the overall frequency of LOH at this locus was only 48%, and many cases with interstitial deletions were heterozygous at this locus; thus, this site may not represent another critically deleted region in MM. STRP analysis of case 31 showed that both alleles in the region from D1S532 to D1S1588 were retained, but karyotypic analysis of this cell line showed...

Fig. 1. LOH analysis of chromosome 1 at 19 CHLC markers in MM. The percentage of LOH (LOH cases/informative cases) at each locus in all 50 MM cases is shown at the right. The allelic losses in 24 cases with interstitial and/or terminal deletions are presented. Case numbers are indicated at the top. Tumor (T) or cell line (C) was used for LOH analysis. The SRO of deletions is indicated at the right by a vertical broken line.
Fig. 2. Representative autoradiographs of STRP analyses that define the SRO of 1p deletions in MM. A, CHLC markers; B, Genethon markers. Case numbers are shown at the top. T, tumor DNA; C, cell line DNA; N, normal lymphocyte DNA. Dots, positions of the alleles; arrowheads, allelic loss.

indicated that only one copy of chromosome 1 was present (data not shown), suggesting that a relatively small segment of 1p resides in one of the marker chromosomes observed in this cell line. One of the breakpoints in case 31 is located between D1S1588 and D1S1587, further implicating this region as being critical in MM.

To obtain a more refined map of the SRO of 1p deletions, another 13 STRP markers located near D1S1588 were selected from the second generation Genethon map (14, 15). All 50 MMs were tested for these markers, but no new deletion was revealed. The LOH patterns in 8 cases with a breakpoint at either side of D1S1588 were used to determine the SRO (Fig. 3). Cases 13 and 18 exhibited losses at all informative Genethon loci (data not shown). Through an analysis of the informative cases, the SRO can be delineated as a region of approximately 4 cM between D1S435 and D1S236. The proximal boundary, D1S236, was determined by the location of the breakpoint in case 9 (Figs. 2 and 3). Case 32 was not informative for D1S424 and D1S415 but showed allelic losses at the proximal loci and retained heterozygosity at D1S435 and more distal loci, suggesting the distal border to be D1S435 (Figs. 2 and 3). Interestingly, in case 31 heterozygosity was retained at D1S424 but was lost at D1S415. The complicated pattern of deletion in this case suggests that a second rearrangement, such as an inversion, might have occurred prior to the deletion event.

Cytogenetic Analyses. The location of the SRO at 1p22 was verified by two-color FISH analysis using YACs containing loci flanking the SRO. When YAC 946C5 (containing D1S435) and YAC 759D7 (containing D1S236) were hybridized to metaphase spreads of normal lymphocytes, both signals were observed on 1p22 (Fig. 4A), indicating that the SRO is located within this band. The two signals appeared to be very close to but distinct from each other, with YAC 946C5 signals located distal to those for YAC 759D7 in most copies of chromosome 1 examined. These observations are consistent with the relative orientation of D1S435 and D1S236 and the 4-cM distance inferred from the genetic map (Fig. 3).

Among all of the cases included in this study, cell line 28 appeared to contain the smallest interstitial deletion involving the region 1p21–22 (Figs. 1 and 3) and thus was used to identify the chromosomal location of the deletion by G-banding and FISH analyses. The modal chromosome number of this cell line was near-triploid, with
in three copies of chromosome 1 in most metaphases. Two copies appeared to be normal. Band 1p22 appeared to be deleted in the remaining copy (Fig. 4B).

In a two-color FISH experiment performed on metaphase spreads from cell line 28, probes derived from YACs 957D9 (containing DIS424) and 885C5 (containing DIS488) hybridized to both normal copies of chromosome 1. The aberrant chromosome 1 hybridized to the 885C5 probe but not to the 957D9 probe (Fig. 4C), confirming the deletion encompassing locus DIS424.

Discussion

Deletion of chromosome 1p21–22 was the most frequent change observed in our previous cytogenetic analyses of primary MM tumor specimens and cell lines (4). In the study presented here, this deletion was verified at the molecular genetic level by LOH analysis using STRP markers spanning the entire short arm of chromosome 1. Moreover, the SRO of deletions was narrowed down to a 4-cM segment between the loci DIS435 and DIS236 by analyzing the densely distributed (CA)n markers located in this region. FISH analysis using YACs containing DIS435 and DIS236 confirmed that the critically deleted region resides within band 1p22.

Among the 50 cases included in this investigation, deletions in 1p were observed in 26 cell lines and 11 tumors. Tumor samples had a lower frequency (11 of 18, 61%) of 1p deletions than cell lines (26 of 32, 81%), which could be due to various factors, such as contamination of tumor tissue by normal infiltrating cells, confounding efforts to identify LOH. Also, our previous karyotypic studies documented heterogeneity within tumors from MM patients, and there could be in vitro selection of subpopulations exhibiting 1p deletions. In the majority of tumor specimens, LOH was easily recognized because the intensity of the band amplified from one allele of the tumor DNA was greatly reduced as compared to its corresponding allele in normal cells. However, PCR amplification products from some tumor DNAs showed less obvious differences in intensity. In this study, LOH was assigned to a locus only if the allelic ratios in tumor and normal DNAs differed more than 30%. Thus, an allelic loss in a tumor specimen could be overlooked if there was contamination by a large amount of infiltrating lymphocytes or cells from adjacent normal tissue. Nevertheless, interstitial deletions were detected in six primary tumor specimens, and the locations of the deletions were comparable to those of the cell lines. Moreover, karyotypic analysis also showed that both fresh tumors and cell lines shared the same characteristic deletions of the 1p21–22 region (4), further supporting the notion that the deletion events occurred before tumor explantation and were preserved in the cell lines.

Recurrent deletions involving 1p have been observed by cytogenetic and/or LOH analyses in several different cancers. Chromosome 1p36 is frequently deleted in neuroblastoma, malignant melanoma, Merkel cell carcinoma, colon cancer, hepatocellular carcinoma, and breast cancer (16). In this study, approximately 45% of MM cases showed LOH from 1p36 (Fig. 1). Although this frequency is considerably less than that observed at 1p22, the possibility exists that a TSG residing in 1p36 may also be involved in the pathogenesis of some MMs. Chromosome 1p22 was reported to be an unique deletion site associated with male germ cell tumors (17). There are no markers in common between the ones used in the present investigation and those used in the deletion mapping study of male germ cell tumors, and the relative locations between these two sets of markers are unknown. Thus, it is unclear at this time whether the same 1p22 TSG may be involved in both of these tumor types. It is also noteworthy that in a recent study of liver carcinomas, deletion of 1p, with a breakpoint at 1p22, was one of the most frequent abnormalities (18), but the critical region has not yet been defined molecularly. Several other regions in chromosome 1p have also been reported to be frequently deleted in different kinds of cancer, e.g., 1p32–35 in neuroblastoma (16), 1p31.3–32.2 and 1p13 in male germ cell tumors (17), and 1p35, 1p31, and 1p13 in breast cancer (19, 20). The 1p31 deletion in breast cancer is quite close physically to the 1p22 deletion we observed in MM. However, the 1p31 markers most frequently deleted in breast cancer (20) are more than 10 cM distal to the SRO defined in our investigation, suggesting that different TSGs are involved in these two malignancies.

It has been well documented that multiple genetic changes contribute to the pathogenesis of various types of malignancies. In MM, the long disease latency and the recurrent nature of losses from several different chromosomes suggest that inactivation of multiple TSGs may be required for mesothelial cell tumorigenesis. Frequent alterations of two TSGs, CDKN2 (p16) and NF2, have been observed in both MM cell lines and primary tumors (7–9). Mutations of other TSGs, such as TP53 and WT1, have also been reported in a few cases of MM (21, 22). The deletion mapping data presented here not only strongly suggest that a putative 1p22 TSG(s) may be altered in a high percentage of MMs but also define its location to a discrete 4-cM region. With the rapid advances in human genome mapping and contig construction, it should now be possible to begin positional cloning of this region. We are currently in the process of constructing...
a YAC contig encompassing the SRO. Such a contig will allow us to generate new polymorphic markers to define an even smaller SRO as well as search for candidate genes residing in this region.

Acknowledgments

We thank Drs. Jin Quan Cheng and Daphne W. Bell for valuable comments.

References

Loss of Heterozygosity Analysis Defines a Critical Region in Chromosome 1p22 Commonly Deleted in Human Malignant Mesothelioma

Wen-Ching Lee, Binaifer Balsara, Zemin Liu, et al.